"Botulinum Toxins, Type A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25.
| Descriptor ID |
D019274
|
| MeSH Number(s) |
D08.811.277.656.300.480.153.100 D08.811.277.656.675.374.153.100 D12.776.097.156.100 D23.946.123.179.050
|
| Concept/Terms |
Botulinum Toxins, Type A- Botulinum Toxins, Type A
- Botulinum Neurotoxin A
- Neurotoxin A, Botulinum
- Clostridium botulinum A Toxin
- Clostridium Botulinum Toxin Type A
- Botulinum A Toxin
- Toxin, Botulinum A
- Botulinum Toxin Type A
|
Below are MeSH descriptors whose meaning is more general than "Botulinum Toxins, Type A".
Below are MeSH descriptors whose meaning is more specific than "Botulinum Toxins, Type A".
This graph shows the total number of publications written about "Botulinum Toxins, Type A" by people in this website by year, and whether "Botulinum Toxins, Type A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 2 | 0 | 2 |
| 2002 | 2 | 0 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 4 | 1 | 5 |
| 2008 | 3 | 0 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 2 | 0 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 4 | 0 | 4 |
| 2022 | 2 | 0 | 2 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Botulinum Toxins, Type A" by people in Profiles.
-
Does the Use of Botulinum Toxin in Treatment of Myofascial Pain Disorder of the Masseters and Temporalis Muscles Reduce Pain, Improve Function, or Enhance Quality of Life? J Oral Maxillofac Surg. 2024 04; 82(4):393-401.
-
In Silico Conformational Features of Botulinum Toxins A1 and E1 According to Intraluminal Acidification. Toxins (Basel). 2022 09 17; 14(9).
-
Incomplete bladder emptying and urinary tract infections after botulinum toxin injection for overactive bladder: Multi-institutional collaboration from the SUFU research network. Neurourol Urodyn. 2022 02; 41(2):662-671.
-
The Effect of Symptomatic Stress Urinary Incontinence on Catheterization Rates After Intradetrusor OnabotulinumtoxinA Injections. Female Pelvic Med Reconstr Surg. 2021 11 01; 27(11):676-680.
-
Development of Objective Structured Assessment of Technical Skills in facial cosmetic procedures: Botulinum toxin neuromodulator and soft-tissue filler injection. J Am Acad Dermatol. 2022 02; 86(2):463-467.
-
The First Injection: Rates of Urinary Retention in Women With Urgency Incontinence Treated With Intravesical OnabotulinumtoxinA Injection. Female Pelvic Med Reconstr Surg. 2021 01 01; 27(1):e118-e121.
-
Concurrent Retropubic Midurethral Sling and OnabotulinumtoxinA for Mixed Urinary Incontinence: A Randomized Controlled Trial. Obstet Gynecol. 2021 01 01; 137(1):12-20.
-
Efficacy, Patient-Reported Outcomes, and Safety for Millennial Subjects Treated With OnabotulinumtoxinA for Moderate to Severe Horizontal Forehead Lines. Dermatol Surg. 2020 05; 46(5):653-661.
-
Symptomatic Brain Hemorrhages from Cavernous Angioma After Botulinum Toxin Injections, a Role of TLR/MEKK3 Mechanism? Case Report and Review of the Literature. World Neurosurg. 2020 Apr; 136:7-11.
-
Impact of Botulinum Toxin Type A Treatment of the Glabella and Crow's Feet on Static Forehead Rhytides. Dermatol Surg. 2019 01; 45(1):167-169.